Akron Participates in Newly Published Study Modelling Cost of Goods for Allogeneic CAR T

Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic

FDA-approved drug may prevent Cytokine Release Syndrome (CRS) associated with cell therapy

Recently published research findings suggest that we may be able to prevent Cytokine Release Syndrome (CRS) through the oral administration of an FDA-approved drug. CAR-T therapy is a promising new approach to cancer treatment. However, a devastating side effect of CAR-T cell infusion is CRS. The patient’s infused activated T cells release interferon gamma (IFN-γ)

A new 3D bio-printing method shows great potential for tissue engineering scaffolds

Electrospinning has been an attractive scaffold fabrication technique for over a decade capable of introducing micro-architectural ques to enhance tissue engineering modalities. Nonetheless, only a handful or architecturally relevant structures can be accomplished with this technique which require complex set-ups in order to be rendered properly. On the other hand, 3D Bio-Printing has emerged as

The immune system’s fountain of youth clears old cells in mice to slow aging

Aging is characterized by a functional decline in many physiological systems. Cellular senescence, a central component of aging, is a cell-intrinsic stress response programmed to impose stable cell-cycle arrest in damaged cells. These senescent cells are not completely dead but do suffer loss of function or irreparable damage, and they have been implicated in diseases

Microneedle patch delivers cardiac stem cells to promote heart repair following heart attack

Myocardial infarctions, commonly called heart attacks, affect thousands of people every year. Myocardial infarctions occur when a blockage in the arteries causes a decrease in blood flow to the heart. This leads to irreversible damage to the heart muscles, loss of cardiac cells, and scarring. Cell therapy seeks to regenerate lost cardiac cells with cardiac

Akron Biotech Attends the MIT Center for Biomedical Innovation’s 2018 BioMAN Summit in Cambridge

The MIT Center for Biomedical Innovation (CBI) leads the Biomanufacturing (BioMAN) program, an initiative that joins leaders from industry, academia, and government to address collective challenges in biologics manufacturing by creating a pre-competitive environment in which stakeholders can share best practices and engage in collaborative work. Akron Biotech attended this year’s summit in Cambridge, MA

SCB Perspectives: ISO Publishes Three-Part Documentary Standard on Ancillary Materials for Cell Manufacturing Processes

This blog post was originally shared at standardscoordinatingbody.org. Claudia Zylberberg, SCB Board Member, Akron Biotech December 17, 2018 I’m pleased to announce that one of the first standards advancement projects SCB was involved in, Ancillary Materials Used in Cellular Therapy Production, has culminated in the publication of a three-part documentary ISO standard (ISO/TS 20399): Part